中国医院用药评价与分析2015，Vol.15Issue(12)：1662-1664,3.DOI:10.14009/j.issn.1672-2124.2015.12.034
肺癌患者化疗后骨髓抑制45例分析
Analysis of Myelosuppression after Chemotherapy in 45 Patients with Lung CancerΔ
摘要
Abstract
OBJECTIVE:To investigate the characteristics and influence factors of myelosuppression after chemotherapy in patients with lung cancer in the Second People's Hospital of Deyang(hereinafter referred to as "our hospital"),and to provide reference for the medication safety.METHODS:The clinical data of myelosuppression after chemotherapy in patients with lung cancer admitted into our hospital during 2013-2014 were retrospectively analyzed.RESULTS:Of the 45 cases with lung cancer,32 cases ( 71.1%) had myelosuppression after chemotherapy,and 19 cases ( 42.2%) were severe.Myelosuppression mainly occurred in two weeks after chemotherapy,and the age stage of 50-59 year-old had the highest incidence rate.The incidence of myelosuppression after chemotherapy of patients with small cell lung cancer was higher than non small cell lung cancer (100.0% VS 63.9%).The incidence of myelosuppression after combined chemotherapy was higher than single agent chemotherapy (87.5%VS 52.4%).The incidence of myelosuppression induced by chemotherapy containing platinum drugs was higher than that without containing platinum (78.8%VS 50.0%),and the differences were statistical significance (P<0.05).CONCLUSIONS:The incidence of myelosuppression after chemotherapy of patients with lung cancer was relatively high.Thus,the medical staff should focus on age,chemotherapy scheme,type of lung cancer and the occurrence time of myelosuppression,so as to reduce the risks of myelosuppression,relief damages on patients by active treatment,and promote medication safety in patients.关键词
肺癌/化疗/骨髓抑制Key words
Lung cancer/Chemotherapy/Myelosuppression分类
药学引用本文复制引用
张奇兵,袁珺,刘伦波,赵寿宁,叶本模..肺癌患者化疗后骨髓抑制45例分析[J].中国医院用药评价与分析,2015,15(12):1662-1664,3.基金项目
德阳市2014年度重点科学技术研究项目(No.2014SZ097-2) （No.2014SZ097-2）
